Is Ocugen, Inc. (OCGN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 6.2% / 30% | 11.1% / 30% | 0.0% / 30% | 17.34% / 5% | ✗ NOT HALAL |
| DJIM | 6.2% / 33% | 11.1% / 33% | 0.0% / 33% | 17.34% / 5% | ✗ NOT HALAL |
| MSCI | 39.4% / 33% | 71.0% / 33% | 0.0% / 33% | 17.34% / 5% | ✗ NOT HALAL |
| S&P | 6.2% / 33% | 11.1% / 33% | 0.0% / 33% | 17.34% / 5% | ✗ NOT HALAL |
| FTSE | 39.4% / 33% | 71.0% / 33% | 0.0% / 50% | 17.34% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 8558.5% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -776.9% | |
| Return on Assets (ROA) | -63.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$57M |
| Free Cash Flow | -$57M |
| Total Debt | $33M |
| Current Ratio | 1.1 |
| Total Assets | $44M |
Price & Trading
| Last Close | $1.96 |
| 50-Day MA | $1.75 |
| 200-Day MA | $1.39 |
| Avg Volume | 7.3M |
| Beta | 2.9 |
|
52-Week Range
$0.57
| |
About Ocugen, Inc. (OCGN)
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Ocugen, Inc. (OCGN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Ocugen, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Ocugen, Inc.'s debt ratio?
Ocugen, Inc.'s debt ratio is 6.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 39.4%.
What are Ocugen, Inc.'s key financial metrics?
Ocugen, Inc. has a market capitalization of $613M, and revenue of $4M. Return on equity stands at -776.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.